Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 10

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  solid tumour
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Radiofrequency ablation does not induce the significant increase of CD4+CD25+Foxp3+ regulatory T cells compared with surgical resection in Hepa 1-6 tumor model

100%
Gao H.-J., Zhang Y.-J., Liang H.-H., Li P., Peng Z.-W., Pang X.-H., Chen M.-S.
Archivum Immunologiae et Therapiae Experimentalis
|
2013
|
tom 61
|
nr 4
2
Content available remote

Drug delivery systems improving chemical and physical properties of anticancer drugs currently investigated for treatment of solid tumors

84%
Aleksandrowicz R., Taciak B., Krol M.
Journal of Physiology and Pharmacology
|
2017
|
tom 68
|
nr 2
3

Monocytic MDSC as a source of immunosuppressive cytokines in chronic lymphocytic leukemia (CLL) microenvironment

84%
Kowalska W., Bojarska-Junak A.
Folia Histochemica et Cytobiologica
|
2020
|
tom 58
|
nr 1
4

Leukemic stem cells show the way

84%
Bonnet D.
Folia Histochemica et Cytobiologica
|
2005
|
tom 43
|
nr 4
5
Content available remote

Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis

67%
Talar-Wojnarowska R., Gasiorowska A., Olakowski M., Lekstan A., Lampe P., Smolarz B., Romanowicz-Makowska H., Kulig A., Malecka-Panas E.
Journal of Physiology and Pharmacology
|
2010
|
tom 61
|
nr 6
6

Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent

67%
Sochanik A., Mitrus I., Smolarczyk R., Cichon T., Snietura M., Czaja M., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2010
|
tom 58
|
nr 3
235-245
7

IGF-I: from diagnostic to triple-helix gene therapy of solid tumors

67%
Trojan L. A., Kopinski P., Wei M. X., Ly A., Glogowska A., Czarny J., Shevelev A., Przewlocki R., Henin D., Trojan J.
Acta Biochimica Polonica
|
2002
|
tom 49
|
nr 4
Alterations in the expression of growth factors and their receptors are associated with the growth and development of human tumors. One such growth factor is IGF-I (insulin-like growth factor I), a 70-amino-acid polypeptide expressed in many tissues, including brain. IGF-I is also expressed at high levels in some nervous system-derived tumors, especially in glioblastoma. When using IGF-I as a diagnostic marker, 17 dif­ferent tumors are considered as expressing the IGF-I gene. Malignant glioma, the most common human brain cancer, is usually fatal. Average survival is less than one year. Our strategy of gene therapy for the treatment of gliomas and other solid tumors is based on: 1) diagnostic using IGF-I gene expression as a differential marker, and 2) application of "triple-helix anti-IGF-I " therapy. In the latter approach, tumor cells are transfected with a vector, which encodes an oligoribonucleotide — an RNA strand containing oligopurine sequence which might be capable of forming a triple helix with an oligopurine and/or oligopyrimidine sequence of the promotor of IGF-I gene (RNA-IGF-I DNA triple helix). Human tumor cells transfected in vitro become down-regulated in the production ofm IGF-I and present immunogenic (MHC-I and B7 expression) and apoptotic characteristics. Similar results were obtained when IGF-I antisense strategy was applied. In both strategies the transfected cells reimplanted in vivo lose tumorigenicity and elicit tumor specific immunity which leads to elimination of established tumors.
8

The effect of angiogenesis inhibitor TNP-470 on the blood vessels of the lungs, kidneys and livers of treated hamsters

67%
Mysliwski A., Kubasik-Juraniec J., Koszalka P., Szmit E.
Folia Morphologica
|
2004
|
tom 63
|
nr 1
The growth of solid tumours and their metastases is dependent on the development of new blood vessels (angiogenesis). Therefore angiogenesis inhibitors are potential antitumour drugs. In our previous studies it was found that the angiogenesis inhibitor TNP-470 given to transplantable melanoma-bearing hamsters can decrease the rate of the tumour growth, although the survival time of the animals treated was not significantly affected. It was found finally that TNP-470 given in the vicinity of the growing tumour can cause complete remission of the melanoma in hamsters treated in this way. To check what side-effects could be evoked by such treatment, an examination of the morphology of the blood vessels of the lungs, kidneys and livers of the treated animals was carried out. It was found that the angiogenesis inhibitor applied did not cause any changes which could be observed by light and electron microscopes in the structure of the examined blood vessels of the treated animals.
9

Cytostatic and cytotoxic effects of [E]-2'-deoxy-2'-[fluoromethylene]-cytidine on a solid tumor and a leukemia cell line

67%
Grieb P., Koronkiewicz M., Skierski J. S.
Acta Biochimica Polonica
|
2000
|
tom 47
|
nr 1
(E)-2'-deoxy-2'-(fluoromethylene)-cytidine (FMdC), a deoxycytidine analog displaying a very high toxicity toward a variety of solid tumor cell lines and xenografts, is activated intracellularly by deoxycytidine kinase (dCK). We have compared cytotoxicity of FMdC towards a human promyeolocytic leukemia line HL-60 and a human colorectal carcinoma line COLO-205. Despite dCK activity being by far the highest in cells of lymphoid origin, the effects of FMdC were detectable at the lowest drug concentration only in a solid tumor cell line, and at higher concentrations they were qualitatively similar in the two tumor lines (increased cell protein content, cell cycle block and apoptosis). Apparently, low dCK activity in solid tumor cells sufficiently activates FMdC to yield cytotoxic effects, while high dCK activity in leukemia cells does not increase its cytotoxicity.
10

Ocena wplywu interferonu ALFA na przebieg choroby nowotworowej u dzieci ze zlosliwymi guzami litymi

59%
Balcerska A., Bohdan Z., Drozynska E., Kozielska E., Szarszewski A., Sierota D.
Acta Biologica et Medica
|
1993
|
tom 20
61-70
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.